Regenxbio up 6% after Novartis receives FDA approval for Zolgensma

Regenxbio (RGNX) will receive royalties from Novartis (NVS) for Zolgensma, which was just approved by the FDA for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy, or SMA, with bi-allelic mutations in the survival motor neuron 1 gene. Following the announcement of the FDA approval, Regenxbio shares are up $2.55, or 6%, to $45.03, while Novartis shares trading in New York are up $3.10, or 3.7%, to $87.54.

https://thefly.com/landingPageNews.php?id=2913947